Clinical Trials Logo
  1. Home
  2. Hematologic Cancer
  3. NCT05942885

Hypnosis: a Path to Appeasement — HYCVA  

Hematologic Cancer Clinical Trial

Official title:
Hypnosis: a Path to Appeasement

Clinical Trial Summary

Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...). The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need. Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05942885
Study type Interventional
Source Hospices Civils de Lyon
Contact Thomas BERT
Phone 04.78.86.43.45
Email thomas.bert01@chu-lyon.fr
Status Recruiting
Phase N/A
Start date October 30, 2023
Completion date July 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04966156 - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT N/A
Recruiting NCT05715047 - Intervention for Fatigue in HCT Recipients N/A
Recruiting NCT05142033 - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed NCT06053918 - Research-Action in Hematology From Hospitalization to Home
Recruiting NCT05175508 - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Phase 2/Phase 3
Not yet recruiting NCT04822974 - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS N/A
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A
Recruiting NCT05753501 - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Phase 1
Recruiting NCT05481502 - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors N/A
Not yet recruiting NCT04412135 - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Not yet recruiting NCT06377059 - Early Detection of Complications During Immunotherapy for Haematological Malignancy N/A
Completed NCT04235153 - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting NCT05626764 - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting NCT04035447 - Symptom Management for YA Cancer Survivors N/A
Not yet recruiting NCT05602168 - Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance N/A
Terminated NCT03955276 - An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Withdrawn NCT01792882 - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Recruiting NCT05493800 - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT Phase 2
Active, not recruiting NCT05690230 - Improving Patient Experience: BMBA N/A